TIDMCOS

Collagen Solutions PLC

19 November 2019

19 November 2019

Collagen Solutions plc

("Collagen Solutions" or the "Company")

Investor results presentation

Collagen Solutions Plc (AIM: COS), the developer and manufacturer of biomaterials and regenerative medicines for the enhancement and extension of human life, announces it will hold an investor results briefing on Tuesday, 3 December 2019.

The Company will announce its interim results for the six months ending 30 September 2019 on 3 December 2019 and will provide an update to investors that day. A briefing will take place at the Brand Exchange, 3 Birchin Lane, London EC3V 9BW at 4.30pm for a 4.45pm start.

Jamal Rushdy, CEO and Hilary Spence, CFO will give an overview of the results and the Company's future plans for growth. This will be followed by drinks and a chance to network.

To register, please call 020 7933 8780 or email collagen@walbrookpr.com.

 
 Collagen Solutions Plc 
 Jamal Rushdy, CEO                                              Via Walbrook 
 Hilary Spence, CFO 
 
 Walbrook PR Ltd               Tel: 020 7933 8780 or collagen@walbrookpr.com 
 Anna Dunphy                                              Mob: 07876 741 001

About Collagen Solutions:

Collagen Solutions Plc is a global supplier, developer, and manufacturer of medical grade collagen, tissues, and related medical devices and components for use in regenerative medicine, tissue engineering, and research. The Company is also expanding its range of biomaterials-based finished medical devices based on its internal and acquired intellectual property for commercialisation with partners via licensing and distribution arrangements, including ChondroMimetic(R). The Company's products are used in a wide variety of applications including orthopaedics, cardiovascular, dental, plastic surgery, wound healing, neurology and urology.

For more information go to: www.collagensolutions.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

NRAEVLFFKFFEFBX

(END) Dow Jones Newswires

November 19, 2019 02:01 ET (07:01 GMT)

Healthcare Inv (LSE:HIO)
Historical Stock Chart
From Dec 2024 to Jan 2025 Click Here for more Healthcare Inv Charts.
Healthcare Inv (LSE:HIO)
Historical Stock Chart
From Jan 2024 to Jan 2025 Click Here for more Healthcare Inv Charts.